Exhibit 99.1 Leap Therapeutics Reports Third Quarter 2024 Financial Results Cambridge, MA – November 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: · Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with ...

CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.Leap Highlights:  Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line pati ...

Financial Performance - Total operating expenses for Q3 2024 were $17,855,000, an increase of 20% compared to $14,833,000 in Q3 2023[10]. - Net loss for Q3 2024 was $18,176,000, compared to a net loss of $13,696,000 in Q3 2023, representing a 33% increase in losses[11]. - Basic and diluted net loss per share for Q3 2024 was $0.44, an improvement from $0.51 in Q3 2023[10]. - Comprehensive loss for Q3 2024 was $18,173,000, compared to $13,350,000 in Q3 2023, indicating a 36% increase in comprehensive losses[11]. - Net loss for the nine months ended September 30, 2024, is $52,124,000, compared to a net loss of $68,949,000 for the same period in 2023, representing a 24% improvement[19]. - The accumulated deficit as of September 30, 2024, was $451.9 million, with a net loss of $52.4 million incurred during the nine months ended September 30, 2024[95]. Research and Development - Research and development expenses for the nine months ended September 30, 2024, were $44,099,000, down 28% from $61,549,000 for the same period in 2023[10]. - The DKN-01 program accounted for $14.8 million in R&D expenses in Q3 2024, up from $11.0 million in Q3 2023, reflecting a $3.8 million increase[86]. - Research and development expenses for Q3 2024 were $14.9 million, an increase of $3.4 million from $11.5 million in Q3 2023[86]. - The company continues to develop DKN-01 and other programs, with ongoing collaborations with BeiGene, NovaRock, and Adimab[3]. - The company is advancing FL-501 into development as a potential best-in-class anti-GDF-15 antibody, with promising preclinical data indicating increased body weight and restored muscle mass in models[75]. - Enrollment completed in the expanded randomized controlled Part B of the DeFianCe study with 188 patients, evaluating DKN-01 in combination with standard care for advanced colorectal cancer[73]. Cash and Liquidity - The company had cash and cash equivalents of $62.823 million at the end of the period, a decrease from $80.743 million at the end of the previous period[19]. - Cash used in operating activities was $44.8 million for the nine months ended September 30, 2024, compared to $33.4 million in the same period in 2023[96]. - Cash and cash equivalents as of September 30, 2024, were $62.8 million, expected to fund operating expenses for at least the next 12 months[95]. - The company experienced a net decrease in cash and cash equivalents of $7.8 million for the nine months ended September 30, 2024, compared to an increase of $15.2 million in 2023[96]. Funding and Equity - Leap Therapeutics completed a private placement in April 2024, raising $39.999 million[19]. - The company plans to seek additional funding through public or private equity financings or collaboration agreements with larger pharmaceutical companies[24]. - The company has not generated any product sales revenues and has not achieved profitable operations since inception[24]. - The total number of common shares outstanding as of September 30, 2024, was 38,264,464[16]. - The company issued 1,972,901 shares of common stock to Flame stockholders as part of the acquisition completed on January 17, 2023[56]. Expenses - General and administrative expenses for Q3 2024 were $2.9 million, a decrease of $0.4 million from $3.3 million in Q3 2023, primarily due to lower professional fees[87]. - The company anticipates an increase in general and administrative expenses in the future as it expands headcount to support ongoing research and development activities[79]. - Stock-based compensation expenses for the nine months ended September 30, 2024, were $3,957,000, slightly up from $3,875,000 in the same period of 2023[19]. Tax and Foreign Currency - The provision for income taxes in Q3 2024 was $708,000, while there was no provision in Q3 2023[10]. - The company reported a foreign currency loss of $8,000 in Q3 2024, compared to a loss of $501,000 in Q3 2023[10]. - The company recorded a foreign currency translation adjustment of $632 thousand for the nine months ended September 30, 2023[19]. Clinical Trials and Product Development - The company has ongoing clinical trials for its lead program DKN-01, targeting multiple cancer types[21]. - Initial data from Part B of the DeFianCe study is expected to be reported in mid-2025, while initial data from Part C of the DisTinGuish study is anticipated in late 2024 or early 2025[73]. - The company has the ability to delay or reduce certain clinical trials or research and development programs if additional funding is not obtained[24].

CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC). "The ...

Exhibit 99.1 Leap Therapeutics Reports Second Quarter 2024 Financial Results Cambridge, MA – August 12, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: · Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFia ...

CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other juris ...

Exhibit 99.1 Leap Therapeutics Reports First Quarter 2024 Financial Results Cambridge, MA – May 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: "We appreciate the strong support of Gilead and the new and existing institutional investors who participated in our recent $40 million financing that will enable the expansion and co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other juri ...

Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Cambridge, MA – March 18, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: "As we reflect on the fourth quarter and the achievements of the past year, we are proud of the strides we've made in advancing DKN- 01 and integrating o ...